Patents Assigned to Agennix, Inc.
-
Publication number: 20100210510Abstract: The present invention relates to methods of treating prophylactically or therapeutically bacteremia, sepsis, septic shock or related conditions such as ARDS by administering orally a composition of lactoferrin alone or in combination with standard therapies or metal chelators to prevent or treat the consequences of bacterially induced systemic inflammatory response syndrome. In particular it is claimed that the therapeutic use of recombinant human lactoferrin alone or in combination with metal chelators or other therapeutic interventions decreases the mortality due to bacteremia, sepsis, septic shock or related conditions such as ARDS.Type: ApplicationFiled: February 8, 2010Publication date: August 19, 2010Applicant: AGENNIX INCInventors: ATUL VARADHACHARY, Karel Petrak
-
Patent number: 7638487Abstract: The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.Type: GrantFiled: November 29, 2007Date of Patent: December 29, 2009Assignee: Agennix, Inc.Inventors: Atul Varadhachary, Karel Petrak
-
Patent number: 7592306Abstract: The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.Type: GrantFiled: December 10, 2003Date of Patent: September 22, 2009Assignee: Agennix, Inc.Inventors: Atul Varadhachary, Federica Pericle
-
Patent number: 7524814Abstract: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.Type: GrantFiled: September 16, 2003Date of Patent: April 28, 2009Assignee: Agennix, Inc.Inventors: Jose Engelmayer, Atul Varadhachary
-
Patent number: 7420033Abstract: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.Type: GrantFiled: February 22, 2007Date of Patent: September 2, 2008Assignee: Agennix, Inc.Inventors: Atul Varadhachary, Peter Glynn, Karel Petrak, Jose Engelmayer
-
Patent number: 7323443Abstract: The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.Type: GrantFiled: December 11, 2003Date of Patent: January 29, 2008Assignee: Agennix Inc.Inventors: Atul Varadhachary, Karel Petrak
-
Patent number: 7262279Abstract: The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbA1c).Type: GrantFiled: April 11, 2006Date of Patent: August 28, 2007Assignee: Agennix, Inc.Inventors: Jose Engelmayer, Atul Varadhachary
-
Patent number: 7244706Abstract: The present invention provides a therapeutic method for treating or preventing a disease resulting from a microbial infection in an individual using an antimicrobial polypeptide. The present invention also provides a method of potentiating the therapeutic action of an antimicrobial drug in a patient. Further provided in the present invention are methods for neutralizing circulating endotoxin in a patient by administering the endotoxin-neutralizing polypeptide or functional variant thereof of the present invention to the patient.Type: GrantFiled: May 13, 2002Date of Patent: July 17, 2007Assignee: Agennix, Inc.Inventor: David M. Mann
-
Patent number: 7238661Abstract: The present invention relates to methods of treating an allergic or non-allergic respiratory disorder by administering orally a composition of lactoferrin alone or in combination with metal chelators to treat respiratory disorders.Type: GrantFiled: May 20, 2003Date of Patent: July 3, 2007Assignee: Agennix, Inc.Inventors: Peter Glynn, Atul Varadhachary
-
Patent number: 7183381Abstract: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.Type: GrantFiled: October 26, 2005Date of Patent: February 27, 2007Assignee: Agennix, Inc.Inventors: Atul Varadhachary, Peter Glynn, Karel Petrak, Jose Engelmayer
-
Patent number: 7034126Abstract: The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbAlc).Type: GrantFiled: May 13, 2004Date of Patent: April 25, 2006Assignee: Agennix, Inc.Inventors: Jose Engelmayer, Atul Varadhachary
-
Patent number: 6399570Abstract: Disclosed is a 6 kDa host-defense polypeptide which is generated by proteolytic digestion of the lactoferrin molecule. The 6 kDa host-defense polypeptide has antimicrobial activity and also endotoxin-neutralizing activity. Also disclosed are functional variants of the 6 kDa host defense polypeptide, which include N-terminal and C-terminal truncations of the 6 kDa polypeptide, and other modifications of the polypeptide, such as amino acid substitutions which preserve or enhance activity.Type: GrantFiled: February 5, 1999Date of Patent: June 4, 2002Assignee: Agennix, Inc.Inventor: David M. Mann
-
Patent number: 6080559Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.Type: GrantFiled: June 29, 1998Date of Patent: June 27, 2000Assignee: Agennix, Inc.Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
-
Patent number: 5955316Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.Type: GrantFiled: August 1, 1996Date of Patent: September 21, 1999Assignee: Agennix, Inc.Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley